Pyrimidone carboxamide compounds as PDE2 inhibitors

US9815796B2 · kind B2 · utility

Assignees

• Merck Sharp & Dohme LLC · US
• MSD R&D (China) Co. Ltd. · CN

Inventors

• Dong-Ming Shen · Edison, US
• Melissa Egbertson · Ambler, US
• Richard Berger · Princeton, US
• Xiaoxia Qian · New York, US
• Yimin Qian · Plainsboro, US
• Bart Harper · New York, US
• Meng Yang · San Diego, US
• Zack Zhiqiang Guo · Morganville, US
• Vanessa L. Rada · Hatfield, US
• Deping Wang · Furlong, US
• Timothy A. Cernak · Boston, US
• Christopher Joseph Sinz · Middletown, US
• Ming Wang · Montgomery, US
• Jonathan E. Wilson · Mattapoisett, US
• Shimin Xu · Beijing, CN

Key dates

• Filing date: Dec 17, 2014
• Grant date: Nov 14, 2017
• Expiry date: Dec 17, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D487/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Disclosed are pyrimidine carboxamide compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2), pharmaceutical compositions and uses thereof.